Immuno-oncology biotech Corvus files for a $115 million IPO - (NASDAQ via NewsPoints Desk)

  • Corvus Pharmaceuticals filed with the US Securities and Exchange Commission to raise up to $115 million in an initial public offering, as reported in NASDAQ.
  • The company, which is developing immuno-oncology therapies that utilise the immune system to fight cancer cells, plans to list on the Nasdaq under the symbol CRVS.

To read more NewsPoints articles, click here.